Two retrospective Chinese NSCLC cohorts who received ICI monotherapy (any line of treatment) showed that patients with KRAS alterations had a longer PFS than those without KRAS alterations (longer than 15 months [n = 14] vs. shorter than 5 months [n = 30]), as well as a longer OS (33 months [n = 12] vs. 22 months [n = 48]), consistent with our remarkable outcome.28, 29. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.